Abstract:: It is widely known that liver cirrhosis, regardless of the etiologies is accompanied by severe hemodynamic changes. The principal pathophysiological mechanisms are the hyperdynamic circulation with increased cardiac output, heart rate along with reduced systemic vascular resistance. Thus, counteractive mechanisms may develop that eventually lead to systolic as well as diastolic dysfunction and rhythm disturbances, in order to keep a steady homeostasis in the human body. : Literally, blunted contractile responsiveness to physical or pharmacological stress, impaired diastolic relaxation and electrophysiological changes, primarily QT interval prolongation, do occur progressively in a cirrhotic patient with no known preexisting cardiac disease. This condition is identified as cirrhotic cardiomyopathy (CCM), an entity different from that seen in alcoholic cardiac muscle disease. : For the past decades, clinicians did study and attempt to understand the pathophysiology and clinical significance of this process. Indeed, various factors have been identified acting at the molecular and cellular level. : Electrocardiography, echocardiography and various serum biomarkers are the main tools that help healthcare practitioners to point to the correct diagnosis. : Noteworthy, the subjects that suffer from cirrhotic cardiomyopathy may progress to heart failure during invasive procedures such as surgery, insertion of a transjugular intrahepatic portosystemic shunting (TIPS) and liver transplantation. Besides, several studies have illustrated that CCM is a contributing factor, or even a precipitant, of hepatorenal syndrome (HRS), a conceivable reversible kidney failure in patients with liver cirrhosis and ascites. : The treatment is the same as it is in the patients with liver cirrhosis and heart failure and there is no particular treatment for cirrhotic cardiomyopathy. Hence, it is of utmost importance to clearly comprehend the pathophysiology of this disease in order to design more accurate diagnostic tools and definitive treatments in a way to prevent the complications of cirrhosis and overt heart failure. : The objective of this review is to describe in a comprehensive way the pathological alterations that occur in the cardiovascular system of cirrhotic patients. It will also point the limitations that remain in the diagnosis and treatment strategies and more importantly, this review will alert the clinicians in the modern era to further observe and record additional pathological changes in this subset of patients.

Prevalence and risk factors for cirrhotic cardiomyopathy: a prospective cross-sectional study

Analysis of Changes in Circular RNA Expression and Construction of Cerna Networks in Human Dilated Cardiomyopathy.

Prevalence and prognostic value of cirrhotic cardiomyopathy as defined according to the proposed new classification

Cirrhotic Cardiomyopathy Predicts Posttransplant Cardiovascular Disease: Revelations of the New Diagnostic Criteria

The prevalence of cirrhotic cardiomyopathy according to different diagnostic criteria

The clinical relevance of the new criteria for cirrhotic cardiomyopathy and future directions

Cirrhotic Cardiomyopathy: The Interplay Between Liver and Cardiac Muscle. How Does the Cardiovascular System React When the Liver is Diseased?

Prevalence of cirrhotic cardiomyopathy and its relationship with serum pro-brain natriuretic peptide, hepatorenal syndrome, spontaneous bacterial peritonitis, and mortality

Diagnosis and Management of Cirrhotic Cardiomyopathy

Longitudinal Investigation of Carriage Rates and Genotypes of Toxigenic Clostridium Difficile in Hepatic Cirrhosis Patients.

[Cirrhotic cardiomyopathy – Clinically fact or academic curiosity? Review: Part 1: definition, epidemiology, pathology and clinical manifestations]

P- 35 COMPLICATIONS ASSOCIATED TO THE LIVER TRANSPLANTATION IN PATIENTS WITH CIRRHOTIC CARDIOMYOPATHY

Multimorbidity of cardiometabolic diseases: prevalence and risk for mortality from one million Chinese adults in a longitudinal cohort study.

Risk factors for hepatocellular carcinoma in cirrhosis: A comprehensive analysis from a decade-long study

Identification and Development of a Novel Risk Model Based on Cuproptosis-Associated RNA Methylation Regulators for Predicting Prognosis and Characterizing Immune Status in Hepatocellular Carcinoma.

Systolic and diastolic dysfunction in advanced liver disease: does cirrhotic cardiomyopathy really exist?

Current Perspectives and Future Possibilities

[An Analysis of Clinical Characteristics and Risk Factors of Cirrhosis-Related Hepatocellular Carcinomas in Patients with Hepatitis C Virus Infection].

Study of Cardiac Dysfunction in Portal Hypertension: A Single-Center Experience From Eastern India

Cardiac dysfunction in patients with cirrhosis and acute decompensation

Prevalence of metabolic syndrome among patients with hepatocellular carcinoma of different etiologies: a retrospective study